PHASE II CLINICAL TRIAL OF MEK 1/2 INHIBITOR AZD6244 IN CANCERS WITH BRAF MUTATIONS IDENTIFIED BY PROSPECTIVE GENOTYPIC ANALYSIS (NCI 8281)

Trial Profile

PHASE II CLINICAL TRIAL OF MEK 1/2 INHIBITOR AZD6244 IN CANCERS WITH BRAF MUTATIONS IDENTIFIED BY PROSPECTIVE GENOTYPIC ANALYSIS (NCI 8281)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Colon cancer; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 28 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top